SCT Cell Manufacturing Presentation: Advancing Autologous CAR-T Cell Therapy from Tech Transfer to Clinical Manufacturing
Friday, May 31, 2024 12:45 PM - 01:00 PM
Exhibit Hall - Theatre B
Global Showcase Presentation
Presenter
During cell therapy research and manufacturing process development, it is crucial to prove that the science functions robustly and the process can be scaled up to the required production volumes. In the unique lab environment of cell therapy, it is equally important to maintain comprehensive and precise electronic records from the equipment used to produce the data in order to streamline regulatory submission and smooth the transition from R&D toward manufacturing.
Session Objectives:
• Provide a deep understanding of the fundamental components shaping Autologous CAR-T Cell Therapy, elucidating the crucial factors influencing its trajectory from technology transfer to clinical manufacturing.
• Facilitate Knowledge and Tech Transfer: enabling participants to glean practical insights and lessons learned from the experiences and successes encountered in the transition phase.
• Encourage Collaboration to foster the exchange of ideas, experiences, and best practices, promoting a collective effort to address challenges and enhance the overall progression of Autologous Cell Therapy
- Ludek Sojka, CEO, SCTbio, Czech Republic
During cell therapy research and manufacturing process development, it is crucial to prove that the science functions robustly and the process can be scaled up to the required production volumes. In the unique lab environment of cell therapy, it is equally important to maintain comprehensive and precise electronic records from the equipment used to produce the data in order to streamline regulatory submission and smooth the transition from R&D toward manufacturing.
Session Objectives:
• Provide a deep understanding of the fundamental components shaping Autologous CAR-T Cell Therapy, elucidating the crucial factors influencing its trajectory from technology transfer to clinical manufacturing.
• Facilitate Knowledge and Tech Transfer: enabling participants to glean practical insights and lessons learned from the experiences and successes encountered in the transition phase.
• Encourage Collaboration to foster the exchange of ideas, experiences, and best practices, promoting a collective effort to address challenges and enhance the overall progression of Autologous Cell Therapy
SPONSORED BY:
No Speakers Found.